Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327
- 1 January 1991
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 18 (3), 215-227
- https://doi.org/10.1002/pros.2990180304
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Kinetic Parameters of 5α-Reductase Activity in Stroma and Epithelium of Normal, Hyperplastic, and Carcinomatous Human Prostates*Journal of Clinical Endocrinology & Metabolism, 1988
- Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.Proceedings of the National Academy of Sciences, 1987
- Experimental Treatment of Prostatic Cancer by Intermittent Hormonal TherapyJournal of Urology, 1987
- Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H)The Prostate, 1987
- Azasteroids: structure-activity relationships for inhibition of 5.alpha.-reductase and of androgen receptor bindingJournal of Medicinal Chemistry, 1986
- Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancersThe Prostate, 1986
- 5α-Reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the ratSteroids, 1986
- Prostatic effects induced in dogs by chronic or acute oral administration of 5α‐reductase inhibitorsThe Prostate, 1986
- Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of dunning R-3327H prostate cancer modelThe Prostate, 1985
- The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancerThe Prostate, 1984